28.03.2024 07:00 | FARN | Issue of Warrants to IPF Funding Update | RNS |
26.03.2024 10:00 | FARN | Faron´s Annual Report 2023 | RNS |
18.03.2024 11:41 | FARN | Faron Pharmaceuticals shares jump on positive data from Bexmab study | Alliance |
18.03.2024 10:05 | TUNE, CLON, FARN | AIM WINNERS & LOSERS: Clontarf raises GBP400,000; Faron jumps | Alliance |
18.03.2024 07:00 | FARN | Additional Positive Data from Phase 1 of BEXMAB | RNS |
14.03.2024 07:00 | FARN | Faron to Host BEXMAB Webcast | Reach |
13.03.2024 20:49 | MACF, CORA, ELEG | EARNINGS AND TRADING: PensionBee nears profit; OptiBiotix Indian deal | Alliance |
13.03.2024 14:00 | FARN | Notice of Annual General Meeting 2024 | RNS |
13.03.2024 07:00 | FARN | Financial Statement January 1 to December 31 2023 | RNS |
06.03.2024 16:06 | EGY, TRN, SUPR | UK earnings, trading statements calendar - next 7 days | Alliance |
04.03.2024 19:59 | BRH, CLA, FARN | TRADING UPDATES: Beowulf raises funds for Kallak iron ore project | Alliance |
04.03.2024 07:00 | FARN | Binding commitments for convertible loans | RNS |
28.02.2024 16:00 | FARN | Replacement - Update to 2024 Financial Calendar | RNS |
27.02.2024 21:12 | FARN, IUG, BEN | TRADING UPDATES: Armadale Capital eyes Mahenge project financing | Alliance |
27.02.2024 18:00 | FARN | Update to Faron’s Financial Calendar for 2024 | RNS |
22.02.2024 17:36 | OMI, FARN, AMIF | EARNINGS AND TRADING: Astra closes Gracell buy, Amicorp "on track" | Alliance |
22.02.2024 14:26 | WEIR, VSVS, SPI | UK earnings, trading statements calendar - next 7 days | Alliance |
21.02.2024 14:00 | FARN | Continued Negotiations Regarding Events of Default | RNS |
19.02.2024 11:23 | FARN | Faron discloses events of default on debt obligations to lender | Alliance |
19.02.2024 10:30 | FARN | Events of Default | RNS |
31.01.2024 07:00 | FARN | Further re: Exercise of options | RNS |
25.01.2024 20:09 | MSYS, NARF, FARN | TRADING UPDATES: Microsaic completes acquisition; Narf revenue soars | Alliance |
25.01.2024 07:00 | FARN | BEXMAB Insights into Patient Profiles | RNS |
19.01.2024 13:00 | FARN | Exercise of options - Issue of equity | RNS |
09.01.2024 10:56 | FARN | Faron says first patient dosed in phase two Bexmab trial for cancer | Alliance |
09.01.2024 07:00 | FARN | First Patient Dosed in Ph 2 of the BEXMAB Trial | RNS |
03.01.2024 07:00 | FARN | Presentation at J.P. Morgan Healthcare Conference | Reach |
22.12.2023 07:00 | FARN | Faron’s Financial Calendar for 2024 | RNS |
11.12.2023 12:01 | FARN | Faron Pharmaceuticals hails positive results of cancer drug trial | Alliance |
11.12.2023 07:00 | FARN | Phase 1 BEXMAB data presented at ASH | RNS |
07.12.2023 19:33 | FARN | IN BRIEF: Faron Pharma celebrates publication of bexmarilimab results | Alliance |
07.12.2023 07:00 | FARN | MATINS Trial in Cell Reports Medicine | Reach |
04.12.2023 07:00 | FARN | Grant of options | RNS |
06.11.2023 11:03 | FARN | IN BRIEF: Faron Pharmaceuticals starts Phase 2 of Bexmab trial | Alliance |
06.11.2023 08:13 | FARN | Faron Initiates Phase 2 Part of BEXMAB Study | RNS |
06.11.2023 07:00 | FARN | Faron Initiates Phase 2 Part of BEXMAB Study | RNS |
02.11.2023 13:00 | FARN | Faron to present data from BEXMAB study at ASH | Reach |
30.10.2023 15:56 | CTG, VIP, ALT | TRADING UPDATES: Bezant optimistic after Hope & Gorob estimate | Alliance |
27.10.2023 13:00 | FARN | Manager's transactions | RNS |
27.10.2023 07:15 | FARN | Exercise of options | RNS |
27.10.2023 07:00 | FARN | Results of Placing | RNS |
26.10.2023 16:30 | FARN | Proposed Issue and Placing | RNS |
11.10.2023 14:01 | FARN | IN BRIEF: Faron Pharmaceuticals' Bexmarilimab shows 50% remission rate | Alliance |
11.10.2023 07:00 | FARN | Faron Announces Positive BEXMAB Study Update | RNS |
03.10.2023 07:00 | FARN | Faron to host webcast on new BEXMAB study data | Reach |
22.09.2023 16:00 | FARN | Board Changes | RNS |
22.09.2023 11:00 | FARN | Results of EGM | RNS |
21.09.2023 12:12 | TRAK, FTC, 88E | TRADING UPDATES: Faron appoints Birge Berns as interim medical officer | Alliance |
21.09.2023 07:00 | FARN | Faron Appoints Interim Chief Medical Officer | RNS |
15.09.2023 15:46 | OIT, TIFS, FARN | UK shareholder meetings calendar - next 7 days | Alliance |
08.09.2023 07:00 | FARN | Change in the Board of Directors | RNS |
06.09.2023 07:00 | FARN | Faron to Present at H.C. Wainwright Conference | Reach |
05.09.2023 14:22 | FARN, EVG | Evgen Pharma hires interim CFO from Faron, chair to retire this month | Alliance |
01.09.2023 10:00 | FARN | Notice of EGM | RNS |
31.08.2023 14:00 | FARN | Exercise of options | RNS |
29.08.2023 10:23 | FARN, PANR | AIM WINNERS & LOSERS: Pelatro plummets on delisting plans | Alliance |
29.08.2023 10:15 | FARN | Faron shares surge on FDA drug designation; loss widens on costs | Alliance |
29.08.2023 07:01 | FARN | Faron 2023 Half-Year Financial Results | RNS |
29.08.2023 07:00 | FARN | FDA Orphan Drug Designation for Bexmarilimab | RNS |
22.08.2023 15:46 | PRTC, FARN, DAL | UK earnings, trading statements calendar - next 7 days | Alliance |
04.08.2023 07:00 | FARN | Notice of Half-Year Financial Results | RNS |
02.08.2023 07:00 | FARN | Faron to Participate at Canaccord Conference | Reach |
25.07.2023 07:00 | FARN | Grant of Options | RNS |
19.07.2023 10:27 | FARN | Faron Pharmaceuticals sees positive data from phase 1 BEXMAB trial | Alliance |
19.07.2023 07:01 | FARN | Faron to Hold BEXMAB Study Conference Call | Reach |
19.07.2023 07:00 | FARN | BEXMAB study update | RNS |
30.06.2023 16:52 | FARN | Holding(s) in Company | RNS |
29.06.2023 18:55 | RNEW, JSE, FARN | TRADING UPDATES: Ecofin US Renewables expects to pay reduced dividend | Alliance |
29.06.2023 07:00 | FARN | Announcement of Placing | RNS |
12.06.2023 07:00 | FARN | Exercise of options | RNS |
09.06.2023 14:34 | RGL, IES, GUN | TRADING UPDATES: Medica shareholders back takeover; Arecor optimistic | Alliance |
09.06.2023 08:00 | FARN | New biomarker data from BEXMAB study at EHA2023 | Reach |
05.06.2023 07:00 | FARN | Board Member to Assume Transactional Advisor Role | RNS |
24.04.2023 14:21 | FARN | Faron Pharmaceuticals test data shows efficacy of bexmarilimab | Alliance |
24.04.2023 07:00 | FARN | Bexmarilimab Efficacy and Safety in MATINS Trial | Reach |